Business

HAVN Life is Therapeutics Ltd for use in clinical studies of the Canadian Business Journal. Secure a purchase order for regulated substance sales to revive.

Vancouver, British Columbia, February 24, 2022 (GLOBE NEWSWIRE) — HAVN Life Science Co., Ltd. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP). (“Company” or “HAVN Life”) Biotechnology companies seeking standardized extraction of psychedelic compounds for research as a potential API to support brain health and cognitive function are theirs. The Canadian supply partner Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) (FSE: 31R) (“Revive”) is used in clinical research studies.We have previously signed Supply contract It was revived in October 2021.

In fulfilling the purchase order, HAVN Life is from a Jamaican facility to its distribution partner, Mycrodose Therapeutics Inc. Exported naturally derived GMP silocibin extract to the United States through (“Mycrodose”), University of Wisconsin-Madison (“UW” -Madison”), Contract Research Institute for Resurrection (“CRO”) .. With the shipment of this naturally occurring silocibin, UW-Madison will use Psychedelicx’s oral dilute and Hydragel delivery system to support various studies sponsored by Revive to treat mental health. Research and formulation work can be performed to complete the delivery mechanism. hindrance.

“We are very pleased to be able to provide naturally occurring GMP psilocybin for this potentially groundbreaking study related to addiction,” said Tim Moore, CEO of HAVN Life. “Such studies will help drive the rescheduling of Schedule I compounds such as psilocybin and psilocin, make treatment more accessible, and mitigate the growing mental health and addiction crisis facing today. I hope it helps, “he adds.

“We are excited to work with HAVN Life to conduct clinical trials, including projects in Antigua,” said Michael Frank, CEO of Revive. “We want to advance the science of plant-based ingredients such as psilocin and psilocybin,” he adds.

“Mycrodose is very pleased to continue its efforts to promote the use of plant-derived psilocybin-based therapies at HAVN Life by expanding the use of psilocybin in research across the United States. DEA’s approval to legally distribute psilocybin for research purposes will help facilitate the use and access of this Schedule I substance by DEA-approved universities, CROs, and other institutions in the United States. ” It states. Mycrodose Therapeutics, CEO, Chad Conner “We hope Revive Therapeutics and the University of Wisconsin-Madison will continue to pursue further clinical trial research and treatment,” he adds.

Revive Therapeutic Ltd. is a life sciences company focused on research and development of treatments for rare and infectious diseases. With the acquisition of Psilocin Pharma Corp. and advances in new oral thin-film delivery systems for psychedelic compounds, Revive is committed to advancing psychedelic-based therapies for mental health and abuse disorders.

Mycrodose is one of the few US pharmaceutical companies whose research has been approved by the US Drug Administration (“DEA”), the Attorney General of California’s Research Advisory Board, and the Food and Drug Administration (“FDA”). A total of eight Schedule I and III compounds will be developed. In addition, DEA has granted Mycrodose permission to import controlled substances of psilocybin and psilocin for clinical trials, research and development, and analysis and distribute them for resale to approved organizations.

HAVN Life’s business in Jamaica Mycelial wellness When PA Benjamin Manufacturing Company Provides cultivation and processing facilities for silo sibe mushrooms.

On behalf of the board of directors
Tim Moore
Chief executive officer

About HAVN Life Science Co., Ltd.

HAVN Life Sciences pursues standardized extraction of psychedelic compounds as an innovative treatment that supports research as a potential API, develops natural health products, supports brain health and enhances mental capacity. It is a biotechnology company.

Through its research arm, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally occurring psychedelic compounds for research to define the future of modern medicine. HAVN Life offers a wide range of high quality mushroom and botanical extracts that support immune function and help support a healthy lifestyle.

Buy our plant-based natural health products and find out more at yourhavnlife.comAnd follow us Facebook, twitter, Instagram When Youtube..

About Revive Therapeutics Co., Ltd.

Revive Therapeutics Ltd. Therapeutics Ltd is a life sciences company focused on the research and development of therapeutics for infectious and rare diseases, with several regulatory issues awarded by the FDA such as orphan drugs and Fast. We are prioritizing drug development efforts to take advantage of our incentives. Follow-up, breakthrough therapy and designation of rare childhood illnesses. We are currently exploring the use of bucillamine for the potential treatment of infectious diseases, initially focusing on severe influenza and COVID-19. With the acquisition of Psilocin Pharma Corp., Revive is developing urinal-based therapies for a variety of diseases and disorders. Revive’s cannabinoid drug portfolio focuses on rare inflammatory diseases and uses cannavidiol (CBD) to treat autoimmune hepatitis (liver disease) and ischemia and reperfusion injury from organ transplants. As a result, the FDA’s orphanage status designation has been granted.

Mycrodose Therapeutics Inc.about

Mycrodose Therapeutics Inc. is a US-based pharmaceutical company headquartered in San Diego, Calif., Using DEA Schedule I and III drugs and other compounds for cancer-related conditions, mental health, and cognitive degeneration. We specialize in developing advanced drug delivery systems to treat diseases.The company believes it is IP protected Sustain Microdosing Technology ™ Is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages, enabling a scalable and scalable business model.

contact address:

Investor Public Relations: ir@havnlife.com
media: savi@emergence-creative.com

Forward-Looking Information: This news release contains “forward-looking information” in the sense of applicable securities law relating to the description of the purchase order for naturally occurring psilocybin from Revive.purchase order”), Exporting naturally derived GMP psilocybin extract from our facility in Jamaica to the United States via Mycrodose (“export”) And UW-Madison delivers a naturally occurring GMP psilocybin extract to UW-Madison to carry out research and formulation work (“”).Delivery and use”), Revive’s Business, Revive’s Business Products and Future, Mycrodose’s Business, Mycrodose’s Business Products and Future, and Our Business, Products and Future of Our Business. We believe that the expectations reflected in our forward-looking information are valid, but there is no guarantee that such expectations will be proven to be correct. Readers should be careful not to place excessive trust in information about future prospects. Such forward-looking statements are susceptible to risk and uncertainty, with actual results, performance, and development, among other things, depending on the risk that the purchase order may not complete as intended. , These descriptions may differ materially from what was intended. All risks that exports may not complete as intended, or no risks that delivery and use may not complete as intended, or none, Revive’s products and plans are mentioned in this news. Different risk releases and revives may not carry out the business plan as expected, and there is a risk that Mycrodose’s products and plans may differ from those described in this news release, and Mycrodose may not be as expected. We may not be able to carry out our business plan and our risk products and plans may not be as described in this news release and we may not be able to carry out our business plan as expected. Except as required by law, we expressly disclaim any obligations and do not intend to update any forward-looking statements or forward-looking information in this news release. We believe that the expectations reflected in our forward-looking information are valid, but there is no guarantee that such expectations will be proven to be correct. The description of this news release is as of the date of this release.

CSE has not reviewed, endorsed, or disapproved the content of this press release.


CBJ News Maker

HAVN Life is Therapeutics Ltd for use in clinical studies of the Canadian Business Journal. Secure a purchase order for regulated substance sales to revive.

Source link HAVN Life is Therapeutics Ltd for use in clinical studies of the Canadian Business Journal. Secure a purchase order for regulated substance sales to revive.

Related Articles

Back to top button